Summary
From 1976 until 1978, 136 adult patients with acute leukemia were treated in four hospitals in Berlin. A complete remission was achieved in 47 patients (35%). Twenty-six patients with non-lymphocytic acute leukemia, who had achieved a complete remission with induction chemotherapy consisting of daunorubicin (45 mg/m2/day, day 1, 2 and 3) and cytosine-arabinoside (100 mg/m2/day, continuous infusion, day 1 to day 7) were entered into a randomized trial. Thirteen patients were treated with an intermittent combination chemotherapy at 4-week intervals; the other group of patients received in addition a specific immunotherapy consisting of neuraminidase-modified allogeneic blast cells. The results revealed that the addition of this kind of immunotherapy did not increase the duration of first remission or survival.
Zusammenfassung
Von 1976 bis 1978 wurden 136 erwachsene Patienten mit akuter Leukämie in vier Berliner Kliniken zytostatisch behandelt. Bei 47 Patienten (35%) konnte eine komplette Remission erzielt werden. Sechsundzwanzig Patienten mit kompletter Remission und einer akuten nicht-lymphatischen Leukämie, bei denen eine Induktionstherapie mit Daunorubidomycin (45 mg/m2/Tag, Tag 1, 2 und 3) und Cytosin-Arabinosid (100 mg/m2/Tag, Dauerinfusion, Tag 1 bis Tag 7) durchgeführt wurde, wurden in einer randomisierten Studie weiter behandelt. Dreizehn Patienten erhielten in vierwochigen Intervallen eine kombinierte Chemotherapie, die andere Gruppe erhielt zusätzlich eine spezifische Immuntherapie, die in der Injektion Neuraminidase-behandelter allogenetischer Blasten bestand. Die Ergebnisse zeigen, daß durch die zusätzliche Immuntherapie in der von uns durchgeführten Form keine Verlängerung der ersten Remission oder der Überlebenszeit erreicht werden konnte.
Similar content being viewed by others
References
Bekesi JG, St. Arneault G, Walter L, Holland JF (1972) Immunogenicity of leukemia L 1210 cells after neuraminidase treatment. J Natl Cancer Inst 49:107–118
Bekesi JG, Holland JF, Roboz JP (1977) Specific immunotherapy with neuraminidase-modified leukemic cells. Med Clin North Am 61:1083–1100
Bekesi JG, Holland JF (1981) Impact of specific immunotherapy in acute myelocytic leukemia (in press)
Bodey GP, Coltman CA, Hewlett JS, Freireich EJ (1976) Progress in the treatment of adults with acute leukemia. Arch Int Med 136:1383–1388
Clarkson BD, Dowling MD, Gee TS, Cunningham IB, Burchenal JH (1975) Treatment of acute leukemia in adults. Cancer 36:775–795
Freeman CB, Harris RG, Colin G, Leyland MJ, Magiver JE, Delamore IW (1973) Active immunotherapy used alone for the maintenance of patients with myeloid leukaemia. Br Med J 4:571–573
Frei E, Sallan SE (1978) Acute lymphoblastic leukemia-treatment. Cancer 42:828–838
Fülle HH (1977) Induktions- und Erhaltungstherapie der akuten myeloischen Leukämie des Erwachsenen durch sequentielle Anwendung zytostatischer Chemotherapiekombinationen. Med Klin 72:642–649
Goodnight JE, Morton DL (1978) Immunotherapy for malignant diseases. Annu Rev Med 29:231–283
Gutterman JU, Rodriguez V, Mavligit GM, Burgess MA, Gehan E, Hersh EM, McCredie KB, Reed R, Smith T, Bodey GP, Freireich EJ (1974) Chemoimmunotherapy of adult acute leukemia: prolongation of remission in myeloblastic leukemia. Lancet 2:1405–1409
Murphy S, Hewlett JS, Balcerzak S (1978) Chemotherapy vs. chemoimmunotherapy remission maintenance for acute leukemia. Proc Am Assoc Cancer Res 19:385–402
Pinkel D (1976) Treatment of acute leukemia. Pediat Clin North Am 23:117–130
Powles RL, Crowther D, Bateman CJT, Beard MEJ, McElwain TJ, Russel J, Lister TA, Whitehouse JMA, Wrigley PFM, Pike M, Alexander P, Hamilton-Failey G (1973) Immunotherapy of acute myelogenous leukaemia. Br J Haematol 35:263–278
Powles RL (1976) Immunologic maneuvres in the management of acute leukemia. Med Clin North Am 60:463–472
Powles RL, Russel J, Lister TA, Oliver T, Whitehouse JMA, Malpass J, Chapuis B, Crowther D, Alexander P (1977) Immunotherapy for acute myelogenous leukemia: a controlled clinical study 2.5 years after entry of the last patient. Br J Cancer 35:265–280
Preisler HD, Rustum Y, Henderson ES, Bjornsson S, Creaven PJ, Higby DJ, Freeman A, Gailani S, Naeher C (1979) Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53:455–464
Riehm H, Gadner H, Welte K (1977) Die West-Berlin Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes — Erfahrungsbericht nach 6 Jahren. Klin Pädiat 189:89–102
Spiers ASD, Costello C, Catovsky D, Galton DAG, Goldman JM (1974) Chronic granulocytic leukaemia: multiple-drug chemotherapy for acute transformation. Br Med J 3:77–80
Vogler WR, Chan JK (1974) Prolonging remission in myeloblastic leukemia by tice strain Bacillus Calmette Guerin. Lancet 2:128–131
Whiteside MG, Cauchi MN, Paton C, Stone J (1976) Chemoimmunotherapy for maintenance in acute myeloblastic leukemia. Cancer 38:1581–1586
Whittaker JA, Slater AJ (1977) The immunotherapy of acute myelogenous leukemia using intravenous BCG. Br J Haematol 35:263–273
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rühl, H., Fülle, H.H., Koeppen, K.M. et al. Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia. Klin Wochenschr 59, 1189–1193 (1981). https://doi.org/10.1007/BF01721213
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01721213